In future studies, we aim to investigate whether O-GlcNAcylation of METTL3 can regulate its resistance to ferroptosis and gemcitabine treatment while also exploring its impact on the tumor microenvironment and potential modulation of immune checkpoint blockade efficacy through an m6A-dependent mechanism. The gene discussed is METTL3; the disease is neoplasm.